콘텐츠로 건너뛰기
Merck
  • Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

Oncotarget (2017-10-27)
Qi Zhang, Ruichao Li, Xu Chen, Sang Beom Lee, Jing Pan, Donghai Xiong, Jiaqi Hu, Mark Steven Miller, Eva Szabo, Ronald A Lubet, Yian Wang, Ming You
초록

Gefitinib showed response in phase II clinical trials and with better clinical response in lung cancer with activating mutations in the tyrosine kinase domain of the EGFR. Questions of toxicity and potential dosing regimens impede the use in a prevention setting. This study will provide scientific evidence for the utility of testing and comparing weekly and daily dosing regimens in clinical trials. We employed the adenocarcinoma (AD) and squamous cell carcinoma (SCC) models to compare the efficacy of Gefitinib in daily or weekly dosing regimens. We also assessed the effectiveness of Gefitinib in altering growth of the H3255 xenograft. Bioluminescent imaging (BLI) and tumor size was evaluated. Relative expression of phospho-EGFR, phospho-ERK and phospho-AKT in the xenograft were evaluated by Western Blot analysis. In the lung AD model, Gefitinib showed significant inhibition of tumor load when treated with weekly or weekly intermittent dosing regimens in AJ/p53

MATERIALS
제품 번호
브랜드
제품 설명

Tricaprylin, European Pharmacopoeia (EP) Reference Standard